Cervical Cancer

A new genomic test for the human papillomavirus (HPV) has shown promising results in early trials, potentially enhancing cervical cancer screening in regions with high mortality rates, such as sub-Saharan Africa, STAT News reports. Early Success The study, led by researchers from Rice University,...

This article was originally published on Cannabis.net and appears here with permission. Cervical cancer affects the cervix, the part of the uterus that is linked to the female genitalia. This cancer begins on the cervix surface, once the cells begin to multiply and some turn into precancerous...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have voluntarily withdrawn their application with the FDA for the expanded use of Libtayo in patients with advanced cervical cancer. The application for the monoclonal antibody as the...

The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S’ (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent or metastatic cervical cancer who previously progressed after...

Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV) in recurrent or metastatic cervical cancer. New data showed some strong...

Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021. Related: Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer. The Phase 2 trial...

The FDA has accepted for review Agenus Inc's (NASDAQ: AGEN) marketing application seeking approval for balstilimab for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Under Priority Review status, the agency's target action date is...

Nanocap Advaxis, Inc. (NASDAQ: ADXS) is seeing strength Wednesday following an announcement concerning its cervical cancer drug. What Happened Advaxis announced the lifting of a partial clinical hold the FDA had imposed on the Phase 3 trial of axalimogene filolisbac, which is being tested in...